R&D | October 29, 2025
Orion secures license to Abzena’s next-generation cancer antibody
The antibody was designed and developed at Abzena’s Cambridge, UK,
The antibody was designed and developed at Abzena’s Cambridge, UK,
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Subscribe To Our Newsletter & Stay Updated
